Disc Medicine, Inc. ((IRON)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Disc Medicine, Inc. has launched a Phase 1b clinical study titled ‘A Phase 1b Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-3405 in Participants With Sickle Cell Disease.’ The study aims to evaluate the safety and effectiveness of DISC-3405 in treating sickle cell disease, a significant health challenge. This research is crucial as it addresses the need for new treatments for this debilitating condition.
The intervention being tested is DISC-3405, a drug administered subcutaneously. It is designed to assess its safety, tolerability, and pharmacological effects in patients with sickle cell disease.
The study follows an interventional, open-label design with a sequential intervention model. It involves dose escalation within participants and includes up to two cohorts. The primary purpose is treatment, with no masking involved.
Key dates for the study include its start date on September 8, 2025, and the last update on September 16, 2025. The study is not yet recruiting, indicating that patient enrollment is forthcoming.
This study update could influence Disc Medicine’s stock performance positively, as successful results may enhance investor confidence. The focus on sickle cell disease, a market with limited treatment options, positions Disc Medicine strategically within the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.